Hepatitis C Therapy
Biochemical and cost factors decide chronic hepatitis C treatment duration
Published in Hepatitis Weekly, August 1st, 2005
According to researchers in the Netherlands, "current guidelines for stopping treatment of chronic hepatitis C are based on hepatitis C ribonucleic acid measurements at 12 and 24 weeks. They conducted research "to explore an alternative approach for making individualized recommendations about treatment duration, based on simple alanine aminotransferase tests and on cost-per-cure."
"We analyzed individual patient data from 13 randomized, controlled trials with interferon alone or combined with ribavirin. Using multiple logistic regression, we built a model that estimated the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2005-08-01)
More Articles from Hepatitis Weekly
- Cancer Detection
The ANN/TM-GTP index accurately predicts recurrent liver cancer - Hepatitis C Therapy
Hepatitis C patients without spontaneous clearance respond to PEG-interferon - Oncology
Oral contraceptive use helps women survive liver cancer - Pediatric Hepatology
Lamivudine impairs glucose metabolism in children with chronic hepatitis B - Virology
Liver-specific interferon gamma expression controls hepatitis B in mice - Addiction Medicine
New findings in the area of addiction medicine detailed - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
